Once upon a Time a Guideline Was Used for the Evaluation of Suspected Choledocholithiasis: A Fairy Tale or a Nightmare? by Canena, J
E-Mail karger@karger.com
 Editorial  
 GE Port J Gastroenterol 2018;25:6–9 
 DOI: 10.1159/000481688 
 Once upon a Time a Guideline Was Used for the 
Evaluation of Suspected Choledocholithiasis: 
A Fairy Tale or a Nightmare? 
 Jorge Canena  
 Centro de Gastrenterologia do Hospital Cuf Infante Santo, Nova Medical School – Faculdade de Ciências Médicas 
da UNL,  Lisbon , Serviço de Gastrenterologia do Hospital Amadora-Sintra,  Amadora , Serviço de Gastrenterologia do 
Hospital de Santo António dos Capuchos, CHLC,  Lisbon , and CINTESIS – Center for Health Technology and Services 
Research,  Porto , Portugal
 
ent in up to 20% of the patients  [2, 3] . The approach used 
in these patients is most important because CBD stones 
are a common cause of hospitalization due to recurrent 
symptoms, cholangitis, and pancreatitis  [5] . Once the di-
agnosis of choledocholithiasis is made, stones should be 
removed by a therapeutic procedure, namely endoscopic 
retrograde cholangiopancreatography (ERCP), which is 
the gold standard for the treatment of CBD stones  [3–5] . 
However, although ERCP is highly effective for the ex-
traction of CBD stones, it is associated with a reasonable 
rate of adverse events, some of them life-threatening  [6, 
7] . For many clinicians, the initial evaluation of patients 
with suspected choledocholithiasis includes serum liver 
biochemical tests (aspartate aminotransferase, alanine 
aminotransferase, alkaline phosphatase, and total biliru-
bin) and a transabdominal ultrasonography (US)  [8–10] 
to select patients for other procedures, such as magnetic 
resonance cholangiopancreatography (MRCP)  [11] or 
endoscopic ultrasound (EUS)  [12] , before they recom-
mend ERCP to the patient; thus, they are trying to avoid 
the overuse of ERCP, which should not be a diagnostic 
procedure because it is associated with complications  [6, 
7] . In 2010, the American Society for Gastrointestinal En-
doscopy (ASGE) published guidelines for the prediction 
of risk stratification for patients being evaluated for CBD 
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 A guideline should always be seen as an educational 
device. Guidelines are prepared by a panel of experts on 
the field based on a critical review of the quality of avail-
able evidence. Guidelines are used to assist endoscopists 
while providing the standard of care to patients and 
should not be used as a rule. However, the question re-
mains: are all guidelines useful or equivalent in quality?
 Gallstone disease is a common clinical problem. In Eu-
rope, ultrasound studies revealed a prevalence of 9–21% 
and an incidence of 0.63/100 persons/year  [1–4] . Cho-
ledocholithiasis or common bile duct (CBD) stones are a 
frequent complication of gallstone disease and are pres-
 Received: September 19, 2017 
 Accepted after revision: September 20, 2017 
 Published online: November 8, 2017 
 Prof. Jorge Canena 
 Centro de Gastrenterologia do Hospital Cuf Infante Santo 
 Nova Medical School – Faculdade de Ciências Médicas da UNL 
 Travessa do Castro 3, PT–1350-070 Lisbon (Portugal) 
 E-Mail jmtcanena   @   live.com.pt  
 © 2017 Sociedade Portuguesa de Gastrenterologia
Published by S. Karger AG, Basel 
 www.karger.com/pjg Th is article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modifi ed material requires written permission.
 Evaluation of Suspected 
Choledocholithiasis 
 GE Port J Gastroenterol 2018;25:6–9 
DOI: 10.1159/000481688
7
stones  [4] . The guideline classifies patients into high risk 
(>50%), intermediate risk (10–50%), and low risk of cho-
ledocholithiasis (<10%) as far as the probability of having 
CBD stones is concerned. Patients at high risk were de-
fined as having any of the very strong predictors of cho-
ledocholithiasis (i.e., CBD stones on transabdominal US, 
clinical ascending cholangitis, or serum bilirubin level >4 
mg/dL) or both strong predictors (i.e., dilated CBD on 
US, namely >6 mm with gallbladder in situ, and bilirubin 
level 1.8–4 mg/dL). Patients at intermediate risk were 
those with the presence of 1 strong predictor or any mod-
erate predictor (abnormal liver biochemical tests other 
than bilirubin, age older than 55 years, and clinical gall-
stone pancreatitis). Patients with low risk were those with 
no predictors present. Based on these guidelines, patients 
at high risk should directly receive ERCP, patients at in-
termediate risk should be submitted to less invasive eval-
uations, namely preoperative MRCP or EUS or as an al-
ternative an intraoperative fluorocholangiography 
(IOFC), and, finally, patients at low risk could directly go 
on to laparoscopic cholecystectomy without the need for 
IOFC. However, before further analysis of the literature 
after the release of these guidelines, the reader should 
keep in mind the following issues: (a) guidelines are edu-
cational devices that may assist endoscopists in taking de-
cisions and not rules; (b) clearly, the ASGE guidelines de-
fine patients with >50% probability of having a CBD 
stone as being at high risk; (c) these guidelines were issued 
with the goal of reducing the overuse of ERCP and, there-
fore, of increasing patients’ safety, and (d) they were is-
sued to minimize the number of unnecessary radiologic 
procedures, which have been associated with excessive 
expenditures, and, therefore, guidelines should also be 
evaluated from a perspective of cost-effectiveness  [13] .
 After the release of the ASGE guidelines, several inves-
tigators tried to validate them in the clinical scenario. In 
one study from the USA, 179 patients with ASGE high-
risk probability criteria were retrospectively analyzed, 
and 99 (56.3%) of these patients had a stone/sludge on 
subsequent confirmation test; therefore, almost 50% of 
these patients were submitted to unnecessary ERCP  [14] . 
The overall accuracy of the guidelines was, in this study, 
62.1% (47.4% sensitivity and 73% specificity). In Spain, a 
prospective study analyzed 256 patients with suspected 
choledocholithiasis  [3] . Of the 208 patients with high-risk 
probability criteria for CBD stones, 124 (59.6%) patients 
were found to have a stone/sludge on ERCP, providing an 
overall accuracy of 59.0% (85.5% sensitivity and 24.3% 
specificity). The remaining 48 patients had an intermedi-
ate probability of CBD stones, and only 21 (43.8%) had a 
stone/sludge, providing an accuracy of 41.0% (14.4% sen-
sitivity and 75.6% specificity). Another study prospec-
tively observed 336 patients with suspected choledocho-
lithiasis  [15] . Of the 244 patients with a high-risk proba-
bility of CBD stones, 185 (75.8%) were found to have 
stones on ERCP (accuracy of 69.05%). Of the 92 patients 
with an intermediate risk for choledocholithiasis, 45 
(48.9%) had stones on ERCP (accuracy 39.95%). Another 
study from the USA retrospectively analyzed 71 patients 
which met ASGE high-risk probability criteria for CBD 
stones  [16] . Of these, only 39 (54%) were found to have a 
stone on ERCP. Overall, in this study, the accuracy of the 
guidelines was 63% (sensitivity 54.9% and specificity 
68.6%). In China, the largest published series included 
1,171 patients with high-risk criteria  [5] . Of these 1,171 
patients, definitive testing (MRCP, EUS, IOFC, and 
ERCP) revealed CBD stones in 1,076 (40%) patients (70% 
sensitivity and 74.3% specificity).
 Taken together, the published studies show that the 
guidelines performed exactly as they were intended to 
perform. I remember that patients at high risk were de-
fined as having a probability of choledocholithiasis >50%. 
Published series reported that patients with high-risk cri-
teria for CBD stones had a documented stone/sludge 
in a range between 40 and 79.8% (average 60.1%) of the 
ERCPs  [2, 3, 5, 14–16] . The majority of the published se-
ries concluded that the ASGE criteria demonstrated a 
probability of >50% of the patients having CBD stones. 
However, authors should also consider that the ASGE 
guidelines performed suboptimally, and the application 
of the current guidelines would lead to unnecessary diag-
nostic ERCPs in more than one-third of the patients, 
which is not acceptable  [2, 3, 5, 14–16] .
 One issue that has not been systematically tested is the 
application of the ASGE guidelines in patients with acute 
cholecystitis. It is important to remember that the above-
mentioned guidelines were not developed nor validated 
for patients with acute cholecystitis. Furthermore, pa-
tients with acute cholecystitis have elevated liver enzymes 
and elevated bilirubin (sometimes >4 mg/dL), which can 
be conflicting for the diagnosis of CBD stones  [17] , and 
abdominal ultrasound can be associated with a poorer de-
tection rate of CBD stones in these patients  [18] . In this 
issue of  GE – Portuguese Journal of Gastroenterology , 
Gouveia et al.  [19] retrospectively analyzed 4,369 patients 
with acute cholecystitis, and only 40 (0.92%) patients had 
a clinical or a sonographic suspicion of choledocholithia-
sis, which is not in line with the reported literature, where 
patients with acute cholecystitis have CBD stones in rates 
ranging from 9 to 58%  [17, 18] . As this was a retrospective 
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analysis, we can always raise the question if the patients 
were correctly encoded for the diagnosis of acute chole-
cystitis. Further, the low number of patients included lim-
ited the strength of the analysis and our conclusions. 
Nonetheless, 31 patients had ASGE high-probability cri-
teria for CBD stones and 9 had an intermediate risk. Not 
surprisingly, of the 31 patients with high-risk criteria, 
only 16 (51.6%) patients were found to have CBD stones, 
providing an accuracy of 57%, and these values were well 
in line with the published literature. However, in the 
study of Gouveia et al.  [19] , the specificity was 31.8% and 
the positive predictive value 52%, which are lower values 
than those previously published and suggest that in this 
group of patients (acute cholecystitis) the ASGE guide-
lines perform even poorer than in the usual clinical sce-
nario. Interestingly, and when using only the liver func-
tion tests (LFTs) in patients with acute cholecystitis, we 
found conflicting results in the literature. In a study from 
Sweden, when using LFTs as predictors of choledocholi-
thiasis in patients with acute cholecystitis, the authors 
found a positive predictive value of 9%  [17] . However, in 
a recent paper from Korea, the authors analyzed patients 
with acute cholecystitis which were divided into 2 groups 
(with and without CBD stones)  [20] . They analyzed LFT 
values on initial admission and the changes of LFT values 
over time after admission. Of all the LFT variables ana-
lyzed, γ-glutamyl transpeptidase was the most reliable 
variable for predicting the presence of CBD stones, with 
a sensitivity of 80.6% and a specificity of 75.3% at the cut-
off level of 224 IU/L. Finally, the authors concluded that 
the LFT values on initial admission and the changes in 
LFT values over time are reliable predictors of CBD stones 
in patients with acute cholecystitis.
 In conclusion, the ASGE guidelines may lead to an un-
necessarily large number of ERCPs, which can be associ-
ated with complications. Further, in the scenario of acute 
cholecystitis, the ASGE guidelines have a low positive 
predictive value and specificity and, therefore, perform 
poorer in the above-mentioned group of patients, leading 
to an excessive overuse of ERCP as described in the paper 
of Gouveia et al.  [19] . It is clear that the ASGE guidelines 
should be re-opened for discussion. The optimal cost-ef-
fectiveness approach for patients with suspected CBD 
stones is unknown, but new modalities should be used. 
He et al.  [5] suggest that a revised algorithm with more 
stringent criteria that includes choledocholithiasis on ab-
dominal US and/or bilirubin levels >4 mg/dL plus CBD 
dilation on abdominal US may improve patient selection 
and reduce the risk of diagnostic ERCP. However, in the 
clinical scenario, most of the authors  [3, 5, 14–16] , includ-
ing myself, advocate the use of alternative diagnostic 
strategies for all patients with high and intermediate 
probability of choledocholithiasis, namely MRCP or EUS 
before ERCP. The ASGE guidelines should be used care-
fully because they are not a fairy tale for sure, and a life-
threatening complication of a diagnostic ERCP is always 
a nightmare.
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